| 1.02 0.01 (0.99%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.34  |
1-year : | 1.56 |
| Resists | First : | 1.14 |
Second : | 1.34 |
| Pivot price | 0.99 |
|||
| Supports | First : | 0.86 |
Second : | 0.68 |
| MAs | MA(5) : | 1 |
MA(20) : | 0.94 |
| MA(100) : | 1.87 |
MA(250) : | 2.39 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 68.1 |
D(3) : | 68.6 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 5.75 | Low : | 0.68 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SKYE ] has closed below upper band by 39.2%. Bollinger Bands are 79.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 62 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.06 - 1.07 | 1.07 - 1.07 |
| Low: | 0.99 - 0.99 | 0.99 - 1 |
| Close: | 1.01 - 1.02 | 1.02 - 1.03 |
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Wed, 21 Jan 2026
Skye Bioscience to Present Research on Nimacimab at Keystone Conference on Obesity Therapeutics - Quiver Quantitative
Wed, 21 Jan 2026
Skye Bioscience to Present Poster at Keystone Obesity Conference - GlobeNewswire
Mon, 19 Jan 2026
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Fri, 16 Jan 2026
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit - PR Newswire
Thu, 15 Jan 2026
SKYE BIOSCIENCE FINAL DEADLINE ALERT: Bragar Eagel & - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 32 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 62.9 (%) |
| Shares Short | 999 (K) |
| Shares Short P.Month | 1,060 (K) |
| EPS | -1.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -54.9 % |
| Return on Equity (ttm) | -94.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -41 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.79 |
| PEG Ratio | 0 |
| Price to Book value | 0.96 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|